Top

Published in:

01-07-2021 | Breast Cancer | Brief Report

Malignant salivary gland tumours in families with breast cancer susceptibility

Authors: Carla B. Ripamonti, Paolo Bossi, Siranoush Manoukian, Laura Locati, Mara Colombo, Maria L. Carcangiu, Andrea Vingiani, Lisa Licitra, Paolo Radice

Published in: Virchows Archiv | Issue 1/2021

Abstract

Salivary gland cancers (SGCs) are rare malignancies with highly heterogeneous histological features. Patients affected with SGCs are at increased risk of secondary malignancies, including breast cancer (BC). Previous studies enlightened a possible link between SGCs and hereditary predisposition to BC. Here, we searched for SGC-affected patients in 1796 high-risk BC families recruited at the Genetic Unit of the Istituto Nazionale dei Tumori of Milan, 516 of which carried pathogenic variants in BRCA1 and/or BRCA2, the main genetic risk factors for BC. We detected five families with an individual affected with SGC, including two male patients, one carrying a constitutional mutation in BRCA1 and the other in BRCA2. Loss of heterozygosity of BRCA wild-type alleles was assessed in the patients’ tumour DNA. We conclude that our observations support the hypothesis that genetic factors associated with BC susceptibility might play a role also in at least a subset of SGCs.

In der Maur CD, Klokman WJ, van Leeuwen FE, Tan IB, Rutgers EJ, Balm AJ (2005) Increased risk of breast cancer development after diagnosis of salivary gland tumour. Eur J Cancer 41:1311–1315. https://doi.org/10.1016/j.ejca.2005.02.023CrossRefPubMed

Yesensky J, Kyrillos A, Kuchta K, Yao K, Wang CH, Bhayani MK (2018) Risk of development of second primary head and neck cancer following an index breast cancer. Otolaryngol Head Neck Surg 158:303–308. https://doi.org/10.1177/0194599817737271CrossRefPubMed

Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K (2020) Cancer surveillance in healthy carriers of germline pathogenic variants in BRCA1/2: a review of secondary prevention guidelines. J Oncol 20(2020):9873954. https://doi.org/10.1155/2020/9873954CrossRef

Shen TK, Teknos TN, Toland AE, Senter L, Nagy R (2014) Salivary gland cancer in BRCA-positive families: a retrospective review. JAMA Otolaryngol Head Neck Surg 140:1213–1217. https://doi.org/10.1001/jamaoto.2014.1998CrossRefPubMed

Dogan S, Ng CKY, Xu B, Kumar R, Wang L, Edelweiss M, Scott SN, Zehir A, Drilon A, Morris LGT, Lee NY, Antonescu CR, Ho AL, Katabi N, Berger MF, Reis-Filho JS (2019) The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Hum Pathol 88:66–77. https://doi.org/10.1016/j.humpath.2019.03.004CrossRefPubMedPubMedCentral

Silva PGB, de Sant’ana RO, Picanço-Albuquerque CG, Silva-Fernandes IJL, Bezerra MJB, Luciano MCDS, Lima MVA (2020) Are pathogenic BRCA1 mutations associated with parotid mucoepidermoid carcinoma? A case report. Oral Surg Oral Med Oral Pathol Oral Radiol S2212–4403(20):31166–31174. https://doi.org/10.1016/j.oooo.2020.08.017CrossRef

Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S (2016) Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: a monocentric Italian study. Eur J Intern Med 32:65–71. https://doi.org/10.1016/j.ejim.2016.03.010CrossRefPubMed

Ripamonti CB, Colombo M, Mondini P, Siranoush M, Peissel B, Bernard L, Radice P, Carcangiu ML (2013) First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer 1(13):46. https://doi.org/10.1186/1471-2407-13-46CrossRef

Foschini MP, Morandi L, Asioli S, Giove G, Corradini AG, Eusebi V (2017) The morphological spectrum of salivary gland type tumours of the breast. Pathology 49:215–227. https://doi.org/10.1016/j.pathol.2016.10.011CrossRefPubMed

10.

Clauditz TS, Reiff M, Gravert L, Gnoss A, Tsourlakis MC, Münscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W (2011) Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 43:459–464. https://doi.org/10.1097/PAT.0b013e3283484a60CrossRefPubMed

11.

Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW (2016) Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22(24):6061–6068. https://doi.org/10.1158/1078-0432.CCR-15-2568CrossRefPubMed

12.

Gatta G, Trama A, Capocaccia R, RARECARENet Working Group (2019) Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol 45:3–11. https://doi.org/10.1016/j.ejso.2017.08.018CrossRefPubMed

13.

Wang K, McDermott JD, Schrock AB, Elvin JA, Gay L, Karam SD, Raben D, Somerset H, Ali SM, Ross JS, Bowles DW (2017) Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol 28:748–753. https://doi.org/10.1093/annonc/mdw689CrossRefPubMed

14.

Kim Y, Song S, Lee M, Swatloski T, Kang JH, Ko YH, Park WY, Jeong HS, Park K (2020) Integrative genomic analysis of salivary duct carcinoma. Sci Rep 10(1):14995. https://doi.org/10.1038/s41598-020-72096-2CrossRefPubMedPubMedCentral

15.

Hoang LN, Gilks BC (2018) Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2. Adv Anat Pathol 25(2):85–95. https://doi.org/10.1097/PAP.0000000000000177CrossRefPubMed

Title: Malignant salivary gland tumours in families with breast cancer susceptibility
Authors: Carla B. Ripamonti
Paolo Bossi
Siranoush Manoukian
Laura Locati
Mara Colombo
Maria L. Carcangiu
Andrea Vingiani
Lisa Licitra
Paolo Radice
Publication date: 01-07-2021
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Salivary Gland Cancer
Salivary Gland Cancer
Published in: Virchows Archiv / Issue 1/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-021-03105-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Malignant salivary gland tumours in families with breast cancer susceptibility

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants

Clear cell clusters in the kidney: a rare finding that should not be misdiagnosed as renal cell carcinoma

Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior

Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment

Expanding spectrum of “spitzoid” lesions: a small series of 4 cases with MAP2K1 mutations

Tumor budding in upper urinary tract urothelial carcinoma: a putative prognostic factor for extraurothelial recurrence and overall survival